Hydrazine → tert-Butyl 1-[6-chloro-4-(hydrazinocarbonyl)pyridin-2-yl]piperidin-4-ylcarbamate
반응식
[NH2:1][NH2:2].[C:3]([O:7][C:8]([NH:10][CH:11]1[CH2:16][CH2:15][N:14]([C:17]2[CH:18]=[C:19]([CH:24]=[C:25]([Cl:27])[N:26]=2)[C:20](OC)=[O:21])[CH2:13][CH2:12]1)=[O:9])([CH3:6])([CH3:5])[CH3:4]>C(O)(C)C>[Cl:27][C:25]1[N:26]=[C:17]([N:14]2[CH2:13][CH2:12][CH:11]([NH:10][C:8](=[O:9])[O:7][C:3]([CH3:4])([CH3:5])[CH3:6])[CH2:16][CH2:15]2)[CH:18]=[C:19]([C:20]([NH:1][NH2:2])=[O:21])[CH:24]=1참가 물질
4
실험 절차
Hydrazine (0.55 ml 17.0 mmol) was added to a solution of methyl 2-{4-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-6-chloroisonicotinate (Intermediate 23, 0.15 g, 0.40 mmol) in isopropanol (3 ml). The mixture was stirred at room temperature overnight then the isopropanol was removed in vacuo to give the title product (130 mg).
후처리
- customthe isopropanol was removed in vacuo
출처 및 근거
- ORD 기록
- ord-d153e6a1920144729eb5b48f5d035018
- 출처 데이터셋
- uspto-grants-2010_05
- 특허 번호
- US07709503B2
반응 노트
불러오는 중…